The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - EMD Serono
Patents, Royalties, Other Intellectual Property - EMD Serono
 
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer; Roche
Expert Testimony - MSD
Travel, Accommodations, Expenses - AstraZeneca
Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC).
 
Byoung Chul Cho
Stock and Other Ownership Interests - Bridgebio; Gencurix; Theravance
Honoraria - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
 
Tae Min Kim
Research Funding - AstraZeneca
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune; Bayer; Boryung; Novartis; Sanofi; Takeda; Voronoi Health Analytics
 
David Vicente
No Relationships to Disclose
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; AstraZeneca; BerGenBio; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Janssen; Lilly; Medscape; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; priME Oncology; Roche; Samsung; Takeda; touchIME
Speakers' Bureau - AbbVie; Abbvie; AstraZeneca; BerGenBio; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Janssen; Lilly; medscape; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Prime Oncology; Roche; Samsung; Takeda; touchIME
Research Funding - EMD Serono (Inst); Merck (Inst)
Other Relationship - GRÍFOLS
 
Dae Ho Lee
Honoraria - Abbvie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chong Kun Dang Pharmaceutical; CJ Healthcare; Green Cross; Janssen; Lilly; Menarini; Merck; MSD; Mundipharma; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Samyang; ST Cube; Takeda
Consulting or Advisory Role - ST Cube
Travel, Accommodations, Expenses - Blueprint Medicines; Takeda
 
Ki Hyeong Lee
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Novartis; Roche
Consulting or Advisory Role - Blueprint Medicines; Boehringer Ingelheim; Novartis
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Lilly; Novartis
 
Maria José Flor
No Relationships to Disclose
 
Massimo A. Di Nicola
No Relationships to Disclose
 
Rosa Maria Alvarez
Honoraria - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; PharmaMar
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; PharmaMar
Research Funding - Abbvie; AstraZeneca; Bluprint Oncology Concepts; Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merrimack; MSD Oncology (Inst); Novartis (Inst); PharmaMar; Roche/Genentech; Takeda (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - PharmaMar; Roche
 
Isabelle Dussault
Employment - Amgen; Amgen (I); Dewpoint Therapeutics; Dewpoint Therapeutics (I); EMD Serono; EMD Serono (I)
Stock and Other Ownership Interests - Amgen; Amgen (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); Merck KGaA; Merck KGaA (I)
Patents, Royalties, Other Intellectual Property - EMD Serono
Travel, Accommodations, Expenses - Amgen; Amgen (I); EMD Serono; EMD Serono (I)
 
Christoph Helwig
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Laureen S. Ojalvo
No Relationships to Disclose
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Merck (Inst); NantBioScience (Inst); Pfizer (Inst)
 
Luis G. Paz-Ares
Leadership - Altum Sequencing; European Medicines Agency (I); Genomica
Honoraria - Advanced Accelerator Applications; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Incyte; Ipsen; Lilly; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Servier; Sysmex
Research Funding - AstraZeneca; Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)